- Home
- CADL vs OLMA Comparison
CADL vs OLMA Comparison
Compare CADL & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CADL
- OLMA
- Stock Information
- Founded
- CADL 1999
- OLMA 2006
- Country
- CADL United States
- OLMA United States
- Employees
- CADL N/A
- OLMA N/A
- Industry
- CADL Biotechnology: Pharmaceutical Preparations
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- CADL Health Care
- OLMA Health Care
- Exchange
- CADL Nasdaq
- OLMA Nasdaq
- Market Cap
- CADL 306.4M
- OLMA 289.0M
- IPO Year
- CADL 2021
- OLMA 2020
- Fundamental
- Price
- CADL $8.09
- OLMA $4.30
- Analyst Decision
- CADL Strong Buy
- OLMA Strong Buy
- Analyst Count
- CADL 4
- OLMA 4
- Target Price
- CADL $21.00
- OLMA $27.50
- AVG Volume (30 Days)
- CADL 918.0K
- OLMA 1.0M
- Earning Date
- CADL 03-13-2025
- OLMA 03-18-2025
- Dividend Yield
- CADL N/A
- OLMA N/A
- EPS Growth
- CADL N/A
- OLMA N/A
- EPS
- CADL N/A
- OLMA N/A
- Revenue
- CADL N/A
- OLMA N/A
- Revenue This Year
- CADL N/A
- OLMA N/A
- Revenue Next Year
- CADL N/A
- OLMA N/A
- P/E Ratio
- CADL N/A
- OLMA N/A
- Revenue Growth
- CADL N/A
- OLMA N/A
- 52 Week Low
- CADL $1.45
- OLMA $3.94
- 52 Week High
- CADL $14.60
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- CADL 49.50
- OLMA 39.74
- Support Level
- CADL $7.85
- OLMA $3.94
- Resistance Level
- CADL $8.69
- OLMA $4.75
- Average True Range (ATR)
- CADL 0.54
- OLMA 0.34
- MACD
- CADL -0.02
- OLMA 0.04
- Stochastic Oscillator
- CADL 54.55
- OLMA 36.42
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.